Related Experiment Videos

Antioxidant stobadine and neurobehavioural development of the rat offspring

M Dubovický1, E Ujházy, P Kovacovský

  • 1Institute of Experimental Pharmacology, Slovak Academy of Sciences, Bratislava. exfadubm@savba.savba.sk

Insights

Stobadine (STO) shows no adverse effects on pregnant or lactating dams or their offspring. This neuroprotective drug supports healthy neurobehavioral development in newborns.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Developmental Biology

Background:

  • Stobadine (STO) is recognized for its neuroprotective and cardioprotective potential, attributed to its significant antioxidative properties.
  • Investigating the safety of potential therapeutic agents during sensitive developmental periods, such as pregnancy and lactation, is crucial.

Purpose of the Study:

  • To evaluate the safety and impact of oral Stobadine (STO) administration on the neurobehavioral development of offspring.
  • To assess potential adverse effects of STO on dams during pregnancy and lactation.

Main Methods:

  • Oral administration of Stobadine (STO) at varying doses (5, 15, and 50 mg/kg/d) to pregnant and lactating dams.
  • Comprehensive assessment of offspring neurobehavioral development, including growth, maturation, sensory and neuromotor functions, activity levels, emotional reactivity, and learning processes.

Main Results:

  • Long-term Stobadine (STO) administration did not negatively impact the course of pregnancy or lactation in the dams.
  • No adverse effects were observed in the neurobehavioral development of the offspring exposed to Stobadine (STO) in utero and during lactation.

Conclusions:

  • Oral Stobadine (STO) administration is safe during pregnancy and lactation.
  • Stobadine (STO) does not adversely affect the neurobehavioral development of offspring, supporting its potential as a neuroprotective agent.

Related Concept Videos